Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. (BBNX) officer Michael Mensinger has filed a notice under Rule 144 to potentially dispose of 5,300 shares of common stock of Beta Bionics through Morgan Stanley Smith Barney LLC on or after September 16, 2026. The filing states an aggregate market value of about $101,919 for these shares. The shares to be sold were acquired by a Series D purchase on September 12, 2023 (5,107 shares) and by exercise of warrants on January 30, 2025 (193 shares). The notice also reports that Mensinger sold 4,375 shares of common stock for $83,619.81 on September 2, 2026.
Beta Bionics, Inc. (BBNX) officer Mark Hopman has filed a notice to sell 28,119 shares of common stock under Rule 144, with an aggregate market value of $540,728.37, when Beta Bionics had 44,989,688 shares outstanding.
The planned sales relate to 25,265 shares acquired through the exercise of stock options on September 16, 2026, and 2,854 shares acquired upon vesting of restricted stock units on June 1, 2025.
Beta Bionics, Inc. (BBNX) is conducting a primary offering of $125,000,000 of common stock under its effective shelf registration, with a 30‑day option for underwriters to buy up to an additional $18,750,000 of shares. Net proceeds will be used for general corporate purposes, including commercialization of its Mint patch pump, manufacturing expansion, R&D, clinical development, product enhancements, potential strategic opportunities, and working capital.
Beta Bionics is a commercial‑stage medical device company focused on automated insulin delivery. Its iLet Bionic Pancreas is FDA‑cleared for Type 1 diabetes and launched in May 2023. In September 2026 it announced FDA clearance of the Mint patch pump and expects full U.S. commercial launch in the first quarter of 2027, targeting production of at least 1.5 million disposable units in 2027 and initial pharmacy‑benefit coverage for about 40% of insured U.S. lives, rising to at least 50% within a year. Real‑world iLet data over two years show average HbA1c improving from 8.9% to a glucose management indicator of 7.3%, with over 84% of users meeting ADA hypoglycemia goals.
Beta Bionics, Inc. (BBNX) reports U.S. FDA clearance of its Mint patch insulin pump and outlines an updated growth strategy and outlook. Mint uses a reusable/disposable design that does not require recharging, integrates with leading continuous glucose monitors, and allows smartphone control. The company expects full U.S. commercial launch in the first quarter of 2027 and anticipates manufacturing capacity for at least 1.5 million disposable Mint units in 2027, with initial U.S. pharmacy-benefit access for about 40% of insured lives, increasing to at least 50% within the first year of full commercialization.
Beta Bionics has submitted a 510(k) application for its 3D Intelligence next‑generation insulin‑dosing algorithm, expected, subject to FDA clearance, to power the iLet 3D and Mint 3D platforms, with U.S. commercialization targeted by the end of 2026 for iLet 3D and alongside Mint’s full launch for Mint 3D. Real‑world data from 14,952 iLet users showed an average HbA1c improvement from 8.9% to a GMI of 7.3%, with over 84% meeting American Diabetes Association hypoglycemia goals, and post‑market data indicated 8.1 users with ≥1 severe hypoglycemia event per 100 patient‑years.
The company raises its 2026 total revenue guidance to $131–136 million from $121–126 million, while maintaining guidance for new patient starts through the pharmacy channel at 37–39% and gross margin at 58.5–59.5%. Management notes an anticipated deferral of up to $10 million of revenue in Q4 2026 as some prospective iLet users await Mint’s launch. Beta Bionics also discloses that a stockholder has filed a securities class action related to prior statements about iLet; the company states it intends to defend the case and that any potential loss is not currently probable or estimable.
Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 775 shares of common stock on September 14, 2026 at a price of $15.52 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2026, and Hopman now holds 86,382 shares directly.
Beta Bionics, Inc. (BBNX) disclosed that Chief Commercial Officer Mark Hopman sold 36,870 shares of common stock on September 9, 2026 in an open market or private transaction at an average price of $18.4628 per share. The transaction was executed pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, and Hopman now directly holds 87,157 shares of Beta Bionics common stock.
Beta Bionics, Inc. (BBNX) officer Mark Hopman has filed a Rule 144 notice indicating an intent to sell up to 40,305 shares of common stock. The filing lists an aggregate market value of approximately $779,095.65 for these shares, to be sold on NASDAQ.
The planned sales include 31,000 shares to be received from the exercise of stock options for cash on September 9, 2026, and 9,305 shares acquired through restricted stock units with an acquisition date of June 1, 2025. The notice states that the securities were and will be acquired upon vesting of restricted stock units and exercises of stock options over the period June 1, 2025 through September 1, 2026, and that acquisition and payment dates were and will be the dates of exercise or sale.
Beta Bionics, Inc. (BBNX) reported that President & CEO Sean Saint sold 5,641 shares of common stock on September 3, 2026 at a weighted average price of $20.0778 per share, in an open-market transaction executed pursuant to a Rule 10b5-1 Plan adopted on September 5, 2025.
After this planned sale, he continued to hold 398,429 shares of Beta Bionics common stock directly.
Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 5,327 shares of common stock on September 2, 2026. The sale was made to cover tax withholding obligations arising from the vesting of restricted stock units. The weighted average sale price was $19.1131 per share, within a range of $18.89 to $19.545. After this sale, Hopman continued to hold 124,027 shares of Beta Bionics common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Beta Bionics, Inc. (BBNX) reported that Chief Medical Officer Steven Jon Russell sold 4,221 shares of common stock on September 2, 2026. The filing states these shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, and not as a discretionary sale of investment holdings.
The weighted average sale price was $19.1131 per share, within a reported range of $18.89 to $19.545. After this transaction, Russell held 169,628 shares of Beta Bionics common stock directly. No transactions were reported under a Rule 10b5-1 trading plan.